Original Article

Mechanisms of oxidative stress-induced *in vivo* mutagenicity by potassium bromate and nitrofurantoin

Takuma Tsuchiya^{1, 2}, Aki Kijima¹, Yuji Ishii¹, Shinji Takasu¹, Yuh Yokoo¹, Akiyoshi Nishikawa¹, Tokuma Yanai², and Takashi Umemura^{1, 3*}

¹ Division of Pathology, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-9501, Japan

² Pathogenetic Veterinary Science, United Graduate School of Veterinary Sciences, Gifu University, 1-1 Yanagido, Gifu-shi, Gifu 501-1193, Japan

³ Department of Animal Nursing, Yamazaki Gakuen University, 4-7-2 Minamiosawa, Hachioji-shi, Tokyo 192-0364, Japan

Abstract: Oxidative stress is well known as a key factor of chemical carcinogenesis. However, the actual role of oxidative stress in carcinogenesis, such as oxidative stress-related *in vivo* mutagenicity, remains unclear. It has been reported that 8-hydroxydeoxyguanosine (8-OHdG), an oxidized DNA lesion, might contribute to chemical carcinogenesis. Potassium bromate (KBrO₃) and nitrofurantoin (NFT) are known as renal carcinogens in rats. Our previous studies showed an increase in mutant frequencies accompanied by an increased level of 8-OHdG in the kidneys of rodents following KBrO₃ or NFT exposure. Furthermore, KBrO₃ and NFT induced different types of gene mutations. Thus, in the present study, we performed reporter gene mutation assays and 8-OHdG measurements following KBrO₃ or NFT exposure using *Nrf2*-proficient and *Nrf2*-deficient mice to clarify the relationship between KBrO₃- or NFT-induced oxidative stress and subsequent genotoxicity. Administration of 1,500 ppm of KBrO₃ in drinking water resulted in an increase in deletion mutations accompanied by an increase in 8-OHdG level, and administration of 2,500 ppm of NFT in diet induced an increase in guanine base substitution mutations without elevation of the 8-OHdG level in *Nrf2*-deficient mice. These results demonstrated that the formation of 8-OHdG, which resulted from the oxidizing potential of KBrO₃, was directly involved in the increase in deletion mutations, although factors related to oxidative stress other than 8-OHdG might be crucial for NFT-induced guanine base substitution mutations. The present study provides new insight into oxidative stress-related *in vivo* mutagenicity. (DOI: 10.1293/tox.2018-0024; J Toxicol Pathol 2018; 31: 179–188)

Key words: bromates, nitrofurantoin, NF-E2-related factor 2, DNA damage, mutagens, kidney

Introduction

The formation of reactive oxygen species (ROS) is considered one of the key factors in chemical carcinogenesis. However, the actual role of oxidative stress remains unclear. Some reports suggest that ROS play an important role in the promotion of chemical carcinogenesis by stimulating the proliferation of initiated cells^{1–3}, while others demonstrate that ROS might be an initiator by forming oxidized DNA lesions^{1, 4–6}. 8-Hydroxydeoxyguanosine (8-OHdG) is the most abundant oxidized DNA lesion among the many oxidized nucleosides known and is fairly stable⁷. Repair of 8-OHdG is carried out by the base excision repair enzymes. In humans,

OGG1, MUTYH, and MTH1 repair 8-OHdG and contribute to the protection of genomic DNA from oxidative stress⁸. The remaining 8-OHdG is considered to cause G:C to T:A transversions by mispairing with adenine and 8-OHdG^{9, 10}.

Potassium bromate (KBrO₃) induces renal cell tumor formation in F344 rats and has been classified as a genotoxic carcinogen because of positive mutagenicity in the Ames¹¹, chromosome aberration¹², and micronucleus tests¹³. Studies demonstrating induction of 8-OHdG by KBrO₃ *in vitro* and *in vivo* suggest that 8-OHdG plays a key role in KBrO₃ mutagenesis and carcinogenesis^{14–17}. It was reported that KBrO₃ produces bromine radicals, which oxidize guanine bases¹⁸. Additionally, our previous study using a two-stage rat renal carcinogenesis model clarified the *in vivo* mutagenicity and initiation following induction of an oxidized DNA lesion in the kidneys of rats administered KBrO₃¹⁹ and showed that high amounts of 8-OHdG resulted in several types of mutations, including deletion mutations, in addition to G:C to T:A transversions¹⁹. The antimicrobial compound nitrofurantoin (NFT) is also known as a renal carcinogen in rats and is prohibited for veterinary use in Japan²⁰. The reduction of the nitro group of NFT induces oxidative stress,

Received: 9 April 2018, Accepted: 26 April 2018

Published online in J-STAGE: 2 June 2018

*Corresponding author: T Umemura (e-mail: umemura@nihs.go.jp)

©2018 The Japanese Society of Toxicologic Pathology

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives

(by-nc-nd) License. (CC-BY-NC-ND 4.0: <https://creativecommons.org/licenses/by-nc-nd/4.0/>).

which exerts antibacterial activity^{21–23}. Moreover, the involvement of oxidative stress is suspected in NFT-induced carcinogenesis. In fact, our recent study showed increased levels of 8-OHdG and *gpt* mutant frequencies (MFs) with guanine base substitution mutations, including G:C to T:A transversions, in the kidneys of *gpt* delta rats treated with NFT²⁴. Nonetheless, the relationship between the formation of 8-OHdG and several types of mutations, including deletion mutations and G:C to T:A transversions, remains unclear.

One of the redox-sensitive transcription factors, nuclear factor erythroid 2-related factor 2 (NRF2), regulates cellular responses to oxidative stress by transactivation of antioxidant response element (ARE)-bearing genes encoding antioxidant-related enzymes, such as NAD(P)H:quinone oxidoreductase 1 (NQO1), heme oxygenase 1 (HO1), and glutathione S-transferase (GST)^{25, 26}. Because of the function of NRF2, *Nrf2*-deficient mice show higher sensitivity to various toxicants that induce oxidative stress^{27–31}; therefore, these mice are quite suitable for investigation of the involvement of oxidative stress in chemical-induced genotoxicity and carcinogenesis.

In the present study, *Nrf2*-proficient and *Nrf2*-deficient mice were exposed to KBrO₃ in drinking water or NFT in diet for 4 and 13 weeks and then subjected to reporter gene mutation assays^{32, 33} and measurement of 8-OHdG levels in the kidney DNA to clarify the relationship between the formation of 8-OHdG and several types of mutations. In addition, the study aimed to elucidate the detailed mechanism of oxidative stress involvement in KBrO₃- or NFT-induced renal carcinogenesis.

Materials and Methods

Chemicals

Potassium bromate (MW 167, CAS No. 7758-01-2) and NFT (C₈H₆N₄O₅, MW 238.2, CAS No. 67-20-9) were purchased from Wako Pure Chemical Industries (Osaka, Japan) and Sigma-Aldrich (St. Louis, MO, USA), respectively.

Animals, diet, and housing conditions

The study protocol was approved by the Animal Care and Utilization Committee of the National Institute of Health Sciences. *Nrf2*-deficient mice with the C57BL/6J background established by Itoh *et al.*³⁴ were crossed with *gpt* delta mice with the C57BL/6J background (Japan SLC, Shizuoka, Japan). *Nrf2*^{-/-} *gpt* delta mice and *Nrf2*^{+/+} *gpt* delta mice were then obtained from the F1 generation and genotyped by polymerase chain reaction (PCR) with DNA taken from the tail of each mouse. All mice were housed in polycarbonate cages (3 to 5 mice per cage) with hardwood chips for bedding in a conventional animal facility maintained at a controlled temperature (23 ± 2°C) and humidity (55 ± 5%), with 12 air changes per hour and a 12-h light/dark cycle. Mice were given free access to CRF-1 basal diet (Charles River Laboratories Japan, Kanagawa, Japan) and tap water.

Experimental design

Six-week-old male mice of each genotype were divided into six groups (four to eight mice per group). KBrO₃ was dissolved in distilled water at concentration of 1,500 ppm, and the prepared water was given to the animals *ad libitum* for 4 or 13 weeks. NFT was mixed in CRF-1 basal diet at concentration of 2,500 ppm, and the prepared diet was given to the animals *ad libitum* for 4 or 13 weeks. Mice of the control group were given distilled water and CRF-1 basal diet. Dose levels of KBrO₃ and NFT were selected as each maximum dose that could be administered to mice for 13 weeks based on a report of intestinal carcinogenesis in *Nrf2*^{-/-} mice²⁷, a subacute toxicity study of KBrO₃³⁵, and a toxicology and carcinogenesis study of NFT conducted by the National Toxicology Program³⁶. In the present study, the 4- and 13-week administration groups were set for the objective of detection of early changes and subsequent changes in 8-OHdG levels and *in vivo* mutagenicity induced by KBrO₃ or NFT, respectively. Body weights were measured every week. Animals were killed by exsanguination under isoflurane (Mylan Inc., Tokyo, Japan) anesthesia. At necropsy, the bilateral kidneys were collected, and their weights were measured. The kidneys-to-body weight ratios (relative weights) were calculated as grams organ weight/grams body weight. A portion of the kidney tissues was frozen with liquid nitrogen and stored at -80°C for use in the *in vivo* mutation assay and 8-OHdG measurement. Another portion was homogenized in ISOGEN (Nippon Gene, Tokyo, Japan) and stored at -80°C until used for isolation of total RNA.

In vivo mutation assays

6-Thioguanine (6-TG) and Spi⁻ selections were performed using the methods described by Nohmi *et al.*³². Briefly, genomic DNA was extracted from the kidneys of animals in each group using a RecoverEase DNA Isolation Kit (Agilent Technologies, Santa Clara, CA, USA), and lambda EG10 DNA (48 kb) was rescued as phages by *in vitro* packaging using Transpack Packaging Extract (Agilent Technologies). For 6-TG selection, packaged phages were incubated with *Escherichia coli* YG6020, which expresses Cre recombinase, and converted to plasmids carrying genes encoding glutamic-pyruvate transaminase and chloramphenicol acetyltransferase. Infected cells were mixed with molten soft agar and poured onto agar plates containing chloramphenicol and 6-TG. In order to determine the total number of rescued plasmids, infected cells were also poured on plates containing chloramphenicol without 6-TG. The plates were then incubated at 37°C for selection of 6-TG-resistant colonies, and the *gpt* MF was calculated by dividing the number of *gpt* mutants after clonal correction by the number of rescued phages. *Gpt* mutations were characterized by amplifying a 739-bp DNA fragment containing the 456-bp coding region of the *gpt* gene³² and sequencing the PCR products with an Applied Biosystems 3730xl DNA Analyzer (Life Technologies, Carlsbad, CA, USA). For Spi⁻ selection, packaged phages were incubated with *E. coli* XL-1 Blue MRA for survival titration and *E. coli* XL-1

Blue MRA P2 for mutant selection. Infected cells were mixed with molten lambda-trypticase agar and poured onto lambda-trypticase agar plates. The next day, plaques (Spi-candidates) were punched out with sterilized glass pipettes, and the agar plugs were suspended in SM buffer. The Spi-phenotype was confirmed by spotting the suspensions on three types of plates on which XL-1 Blue MRA, XL-1 Blue MRA P2, or WL95 P2 strain was spread with soft agar. Spi-mutants, which manifested as clear plaques, were counted on every plate.

Measurement of 8-OHdG

Three animals in each group were selected randomly, and kidneys of those animals were used for the measurement of 8-OHdG. Renal DNA of *Nrf2*^{-/-} *gpt* delta mice and *Nrf2*^{+/+} *gpt* delta mice was extracted and digested as described previously³⁷. Briefly, nuclear DNA was extracted with a DNA Extractor WB Kit (Wako Pure Chemical Industries). For further prevention of artifactual oxidation in the cell lysis step, deferoxamine mesylate (Sigma-Aldrich) was added to the lysis buffer. The DNA was digested to deoxynucleotides by treatment with nuclease P1 and alkaline phosphatase, using an 8-OHdG Assay Preparation Reagent Set (Wako Pure Chemical Industries). The levels of 8-OHdG (8-OHdG/10⁵ dG) were measured by high-performance liquid chromatography with an electrochemical detection system (Coulchem II, ESA, Bedford, MA, USA) as previously reported¹⁹.

RNA isolation and quantitative real-time PCR for evaluation of mRNA expression

Total RNA was extracted using ISOGEN according to the manufacturer's instructions. cDNA of total RNA was obtained using a High-Capacity cDNA Reverse Transcription Kit (Life Technologies).

All PCR reactions were performed with an Applied Biosystems 7900HT FAST Real-Time PCR System with primers for mouse *Nqo1* (coding NAD(P)H:quinone oxidoreductase 1) obtained from TaqMan® Gene Expression As-

says and TaqMan® Rodent GAPDH Control Reagents. The expression levels of the target gene were calculated by the relative standard curve method and were determined as ratios to *Gapdh* levels. Data are presented as fold-change values of treated samples relative to controls.

Statistical analysis

The significance of differences in the results for body weights, kidney weights, mRNA expression levels, 8-OHdG levels, *gpt* and Spi- MFs, and *gpt*- and Spi--mutation spectra were analyzed by Student's *t*-test depending on the homogeneity. *P* values < 0.05 were considered significant.

Results

Body and kidney weights

Body and kidney weights of *Nrf2*-proficient and *Nrf2*-deficient mice treated with KBrO₃ or NFT for 4 or 13 weeks are summarized in Fig. 1 and Table 1. For both genotypes and time points, no significant change was observed in body and kidney weights of treated and respective control animals.

Quantitative real-time PCR for evaluation of *Nqo1* mRNA expression

Expression levels of *Nqo1* in the kidneys are shown in Fig. 2. In *Nrf2*^{+/+} mice, the expression level of *Nqo1* was significantly increased by 4 or 13 weeks of exposure to KBrO₃ (*P*<0.01) and 13 weeks of exposure to NFT (*P*<0.05). Four weeks of exposure to NFT resulted in a tendency toward increased expression of *Nqo1* in *Nrf2*^{+/+} mice. In *Nrf2*^{-/-} mice, increased *Nqo1* expression was not induced by KBrO₃ or NFT treatment at either time point. The *Nqo1* expression levels of control, KBrO₃-treated, and NFT-treated *Nrf2*^{-/-} mice were significantly lower (*P*<0.01) than those of the corresponding *Nrf2*^{+/+} mice at both time points.

Fig. 1. Growth curves for *Nrf2*^{+/+} or *Nrf2*^{-/-} mice treated with KBrO₃ or NFT for 4 weeks (A) or 13 weeks (B). For both genotypes, there were no significant differences in body weight between treated and untreated mice at either time point.

Measurement of 8-OHdG in kidney DNA

The results of 8-OHdG measurement in the kidneys are shown in Fig. 3. At both time points, KBrO₃ treatment

significantly increased the level of 8-OHdG in the kidneys of both genotypes, and the degrees of 8-OHdG increase were as follows: 4 weeks *Nrf2*^{+/+}, × 2.8; 4 weeks *Nrf2*^{-/-},

Table 1. Final Body and Kidney Weights of Male *Nrf2*^{+/+} or *Nrf2*^{-/-} *gpt* Delta Mice Treated with KBrO₃ or NFT for 4 or 13 Weeks

		<i>Nrf2</i> ^{+/+}			<i>Nrf2</i> ^{-/-}		
		Control	1,500 ppm KBrO ₃	2,500 ppm NFT	Control	1,500 ppm KBrO ₃	2,500 ppm NFT
4 weeks	No. of animals	4	5	5	4	4	5
	Final body weights (g)	27.43 ± 2.59 ^b	25.70 ± 2.35	23.56 ± 2.15	26.40 ± 2.18	24.05 ± 1.26	22.80 ± 1.46
	Kidneys (g)	0.33 ± 0.03	0.32 ± 0.04	0.33 ± 0.04	0.32 ± 0.03	0.32 ± 0.04	0.32 ± 0.04
	Kidneys (g%) ^a	1.22 ± 0.11	1.26 ± 0.09	1.38 ± 0.06	1.20 ± 0.10	1.32 ± 0.16	1.38 ± 0.13
13 weeks	No. of animals	8	8	8	6	8	8
	Final body weights (g)	33.53 ± 3.45	29.18 ± 2.45	28.28 ± 1.67	30.05 ± 2.38	24.91 ± 1.80	26.55 ± 1.39
	Kidneys (g)	0.35 ± 0.03	0.34 ± 0.03	0.38 ± 0.05	0.35 ± 0.05	0.34 ± 0.06	0.33 ± 0.04
	Kidneys (g%) ^a	1.06 ± 0.08	1.16 ± 0.08	1.35 ± 0.12	1.18 ± 0.15	1.38 ± 0.30	1.24 ± 0.14

^aKidneys-to-body weight ratios (relative weights) are given as grams organ weight/grams body weight. ^bMean ± SD.

Fig. 2. Changes in mRNA levels of the *Nrf2*-target gene *Nqo1* in the kidneys of *Nrf2*^{+/+} or *Nrf2*^{-/-} mice treated with KBrO₃ or NFT for 4 weeks (A) or 13 weeks (B). Values are means ± SD. *Significantly different ($P < 0.05$) from the respective control group. **Significantly different ($P < 0.01$) from the respective control group. ##Significantly different ($P < 0.01$) from the respective *Nrf2*^{+/+} animals.

Fig. 3. 8-OHdG levels in the kidneys of *Nrf2*^{+/+} or *Nrf2*^{-/-} mice treated with KBrO₃ or NFT for 4 weeks (A) or 13 weeks (B). Values are means ± SD. **Significantly different ($P < 0.01$) from the respective control group. ††Significantly different ($P < 0.01$) from the respective control group.

× 3.6; 13 weeks *Nrf2*^{+/+}, × 2.1; 13 weeks *Nrf2*^{-/-}, × 3.3 (vs. respective control). On the other hand, NFT treatment did not increase the level of 8-OHdG in the kidneys of either genotype at either time point. There was no significant difference in 8-OHdG level between the *Nrf2*-proficient and *Nrf2*-deficient mice of each treatment group.

In vivo mutation assay of kidneys

The results of the *gpt* assay of the kidneys of *Nrf2*-proficient and *Nrf2*-deficient mice treated with KBrO₃ or NFT are shown in Tables 2 to 5. At both time points, KBrO₃-treated mice showed a significant increase or tendency toward increase in *gpt* MFs compared with those in the respective control groups (Table 2). The degrees of increase in *gpt* MFs caused by 13 weeks of treatment with KBrO₃ were as follows: *Nrf2*^{+/+}, × 2.2; *Nrf2*^{-/-}, × 4.4 (vs. respective control; Table 2). Specific MFs of deletion mutations were increased in the spectrum analysis of *gpt* mutants in KBrO₃-treated mice (Table 3 and 4). The frequencies of deletion mutations of more than two base pairs were increased by 13

Table 2. *Gpt* MFs in the Kidneys of *Nrf2*^{+/+} or *Nrf2*^{-/-} *gpt* Delta Mice Treated with KBrO₃ or NFT for 4 or 13 Weeks

Treatment period	Genotype	Treatment	No. of animals	MF#
4 weeks	<i>Nrf2</i> ^{+/+}	Control	4	0.36 ± 0.09
		1,500 ppm KBrO ₃	5	0.70 ± 0.19*
		2,500 ppm NFT	5	0.55 ± 0.27
	<i>Nrf2</i> ^{-/-}	Control	4	0.33 ± 0.08
		1,500 ppm KBrO ₃	4	0.59 ± 0.15
		2,500 ppm NFT	5	0.55 ± 0.06
13 weeks	<i>Nrf2</i> ^{+/+}	Control	8	0.69 ± 0.43
		1,500 ppm KBrO ₃	8	1.57 ± 0.67**
	<i>Nrf2</i> ^{-/-}	Control	5	0.48 ± 0.18
		1,500 ppm KBrO ₃	8	1.86 ± 0.78††
	<i>Nrf2</i> ^{+/+}	Control	8	0.38 ± 0.17
		2,500 ppm NFT	7	1.04 ± 0.24**
	<i>Nrf2</i> ^{-/-}	Control	5	0.39 ± 0.13
		2,500 ppm NFT	8	1.40 ± 0.30††

P* < 0.05 vs. respective control group; *P* < 0.01 vs. respective control group. ††*P* < 0.01 vs. respective control group; MF, Mutant frequency; #Mean ± SD. *Gpt* assays were performed in three divided groups: the 4-week treatment group, 13-week treatment of KBrO₃ group, and the 13-week treatment of NFT group.

Table 3. Mmutation Spectra of *gpt* Mutant Colonies in the Kidneys of *Nrf2*^{+/+} Or *Nrf2*^{-/-} *gpt* Delta Mice Treated with KBrO₃ or NFT for 4 Weeks

		Control		1,500 ppm KBrO ₃		2,500 ppm NFT	
		Number (%)	Mutation frequencies (10 ⁻⁵)	Number (%)	Mutation frequencies (10 ⁻⁵)	Number (%)	Mutation frequencies (10 ⁻⁵)
<i>Nrf2</i> ^{+/+}	Base substitution						
	Transversions						
	G:C to T:A	7 (18.4)	0.06 ± 0.03	16 (18.6)	0.13 ± 0.04	16 (21.6)	0.12 ± 0.07
	G:C to C:G	2 (5.3)	0.02 ± 0.03	2 (2.3)	0.01 ± 0.02	7 (9.5)	0.05 ± 0.03
	A:T to T:A	2 (5.3)	0.02 ± 0.02	10 (11.6)	0.08 ± 0.05	2 (2.7)	0.01 ± 0.02
	A:T to C:G	0	0	2 (2.3)	0.02 ± 0.03	4 (5.4)	0.03 ± 0.05
	Transitions						
	G:C to A:T	15 (39.5)	0.13 ± 0.02	17 (19.8)	0.14 ± 0.07	26 (35.1)	0.18 ± 0.07
	A:T to G:C	2 (5.3)	0.02 ± 0.03	6 (7.0)	0.05 ± 0.03	4 (5.4)	0.03 ± 0.02
	Deletion						
	Single bp ^a	5 (13.2)	0.05 ± 0.04	16 (18.6)	0.13 ± 0.05	10 (13.5)	0.08 ± 0.06
	Over 2 bp ^b	2 (5.3)	0.02 ± 0.02	7 (8.1)	0.05 ± 0.04	3 (4.1)	0.02 ± 0.02
	Insertion	1 (2.6)	0.01 ± 0.01	7 (8.1)	0.05 ± 0.04 *	0	0
	Complex	2 (5.3)	0.02 ± 0.02	3 (3.5)	0.03 ± 0.05	2 (2.7)	0.02 ± 0.05
	Total	38	0.36	86	0.70	74	0.55
<i>Nrf2</i> ^{-/-}	Base substitution						
	Transversions						
	G:C to T:A	7 (15.9)	0.06 ± 0.03	6 (10.2)	0.05 ± 0.04	19 (25.7)	0.14 ± 0.07
	G:C to C:G	2 (4.5)	0.01 ± 0.02	3 (5.1)	0.03 ± 0.03	5 (6.8)	0.04 ± 0.03
	A:T to T:A	0	0	7 (11.9)	0.06 ± 0.08	6 (8.1)	0.04 ± 0.05
	A:T to C:G	2 (4.5)	0.02 ± 0.03	1 (1.7)	0.01 ± 0.02	2 (2.7)	0.02 ± 0.02
	Transitions						
	G:C to A:T	20 (45.5)	0.14 ± 0.06	10 (16.9)	0.10 ± 0.03	22 (29.7)	0.16 ± 0.02
	A:T to G:C	2 (4.5)	0.01 ± 0.02	5 (8.5)	0.05 ± 0.02	5 (6.8)	0.04 ± 0.04
	Deletion						
	Single bp ^a	6 (13.6)	0.04 ± 0.04	19 (32.2)	0.21 ± 0.09 ††	11 (14.9)	0.08 ± 0.05
	Over 2 bp ^b	1 (2.3)	0.01 ± 0.01	5 (8.5)	0.06 ± 0.06	1 (1.4)	0.01 ± 0.02
	Insertion	1 (2.3)	0.01 ± 0.01	2 (3.4)	0.02 ± 0.02	2 (2.7)	0.01 ± 0.02
	Complex	3 (6.8)	0.02 ± 0.01	1 (1.7)	0.01 ± 0.02	1 (1.4)	0.01 ± 0.02
	Total	44	0.33	59	0.59	74	0.55

**P* < 0.05 vs. respective control group; ††*P* < 0.01 vs. respective control group. ^aSingle base pair deletion mutation; ^bDeletion mutation of more than two base pairs.

weeks of treatment with KBrO₃ in both genotypes (Table 4). Furthermore, in both genotypes, *gpt* MFs were increased by 13 weeks of treatment with NFT, despite no change at 4 weeks (Table 2). The degrees of increase in *gpt* MFs caused by 13 weeks of treatment with NFT were as follows: *Nrf2*^{+/+}, × 2.1; *Nrf2*^{-/-}, × 3.3 (vs. respective control; Table 2). In both genotypes, guanine base substitution mutations, including G:C to T:A or G:C to C:G transversion mutations, were increased by 13 weeks of treatment with NFT (Table 5).

The results of the Spi⁻ assay of the kidneys of *Nrf2*-proficient and *Nrf2*-deficient mice treated with KBrO₃ or NFT are shown in Tables 6 to 8. At both time points, KBrO₃-treated mice showed a significant increase or tendency toward increase in Spi⁻ MFs compared with those in the respective control groups (Table 6). The degrees of increase in Spi⁻ MFs caused by 13 weeks of treatment with KBrO₃ were as follows: *Nrf2*^{+/+}, × 3.0; *Nrf2*^{-/-}, × 4.1 (vs. respective control; Table 6). In the spectrum analysis of Spi⁻ mutants

Table 4. Mutation Spectra of *gpt* Mutant Colonies in the Kidneys of *Nrf2*^{+/+} or *Nrf2*^{-/-} *gpt* Delta Mice Treated with KBrO₃ for 13 Weeks

	<i>Nrf2</i> ^{+/+}				<i>Nrf2</i> ^{-/-}			
	Control		1,500 ppm KBrO ₃		Control		1,500 ppm KBrO ₃	
	Number (%)	Mutation frequencies (10 ⁻⁵)	Number (%)	Mutation frequencies (10 ⁻⁵)	Number (%)	Mutation frequencies (10 ⁻⁵)	Number (%)	Mutation frequencies (10 ⁻⁵)
Base substitution								
Transversions								
G:C to T:A	15 (25.9)	0.18 ± 0.16	20 (10.7)	0.16 ± 0.11	13 (28.9)	0.13 ± 0.06	15 (8.2)	0.15 ± 0.11
G:C to C:G	2 (3.4)	0.03 ± 0.06	5 (2.7)	0.04 ± 0.05	1 (2.2)	0.01 ± 0.02	2 (1.1)	0.02 ± 0.03
A:T to T:A	0	0	11 (5.9)	0.10 ± 0.11*	3 (6.7)	0.03 ± 0.03	28 (15.4)	0.27 ± 0.16†
A:T to C:G	0	0	10 (5.3)	0.07 ± 0.06**	0	0	1 (0.5)	0.01 ± 0.03
Transitions								
G:C to A:T	19 (32.8)	0.22 ± 0.21	33 (17.6)	0.27 ± 0.13	19 (42.2)	0.20 ± 0.08	27 (14.8)	0.29 ± 0.16
A:T to G:C	4 (6.9)	0.05 ± 0.08	7 (3.7)	0.06 ± 0.09	3 (6.7)	0.04 ± 0.03	4 (2.2)	0.05 ± 0.06
Deletion								
Single bp ^a	11 (19.0)	0.12 ± 0.11	69 (36.9)	0.60 ± 0.34**	3 (6.7)	0.03 ± 0.03	62 (34.1)	0.65 ± 0.41††
Over 2 bp ^b	2 (3.4)	0.03 ± 0.05	20 (10.7)	0.17 ± 0.07**	1 (2.2)	0.01 ± 0.03	29 (15.9)	0.30 ± 0.13††
Insertion								
Complex	4 (6.9)	0.04 ± 0.07	8 (4.3)	0.07 ± 0.07	1 (2.2)	0.01 ± 0.02	6 (3.3)	0.06 ± 0.10
Complex	1 (1.7)	0.01 ± 0.02	4 (2.1)	0.03 ± 0.04	1 (2.2)	0.01 ± 0.03	8 (4.4)	0.07 ± 0.05†
Total	58	0.69	187	1.57	45	0.48	182	1.86

P*<0.05 vs. respective control group; *P*<0.01 vs. respective control group; †*P*<0.05 vs. respective control group; ††*P*<0.01 vs. respective control group. ^aSingle base pair deletion mutation; ^bDeletion mutation of more than two base pairs.

Table 5. Mutation Spectra of *gpt* Mutant Colonies in the Kidneys of *Nrf2*^{+/+} or *Nrf2*^{-/-} *gpt* Delta Mice Treated with NFT for 13 Weeks

	<i>Nrf2</i> ^{+/+}				<i>Nrf2</i> ^{-/-}			
	Control		2,500 ppm NFT		Control		2,500 ppm NFT	
	Number (%)	Mutation frequencies (10 ⁻⁵)	Number (%)	Mutation frequencies (10 ⁻⁵)	Number (%)	Mutation frequencies (10 ⁻⁵)	Number (%)	Mutation frequencies (10 ⁻⁵)
Base substitution								
Transversions								
G:C to T:A	9 (22.0)	0.08 ± 0.07	31 (28.2)	0.29 ± 0.05**	8 (20.5)	0.07 ± 0.05	47 (30.9)	0.43 ± 0.15††
G:C to C:G	4 (9.8)	0.04 ± 0.05	28 (25.5)	0.26 ± 0.06**	3 (7.7)	0.02 ± 0.03	38 (25.0)	0.37 ± 0.17††
A:T to T:A	0	0	5 (4.5)	0.05 ± 0.07	1 (2.6)	0.01 ± 0.02	7 (4.6)	0.07 ± 0.06†
A:T to C:G	1 (2.4)	0.01 ± 0.02	2 (1.8)	0.02 ± 0.04	0	0	3 (2.0)	0.02 ± 0.03
Transitions								
G:C to A:T	19 (46.3)	0.18 ± 0.10	26 (23.6)	0.24 ± 0.12	16 (41.0)	0.17 ± 0.07	27 (17.8)	0.25 ± 0.09
A:T to G:C	1 (2.4)	0.01 ± 0.02	4 (3.6)	0.04 ± 0.04	0	0	3 (2.0)	0.03 ± 0.04
Deletion								
Single bp ^a	4 (9.8)	0.04 ± 0.04	7 (6.4)	0.06 ± 0.05	9 (23.1)	0.09 ± 0.09	10 (6.6)	0.09 ± 0.05
Over 2 bp ^b	2 (4.9)	0.03 ± 0.05	2 (1.8)	0.02 ± 0.03	1 (2.6)	0.02 ± 0.03	3 (2.0)	0.03 ± 0.04
Insertion								
Complex	0	0	1 (0.9)	0.01 ± 0.02	1 (2.6)	0.01 ± 0.02	5 (3.3)	0.04 ± 0.06
Complex	1 (2.4)	0.01 ± 0.03	4 (3.6)	0.04 ± 0.07	0	0	9 (5.9)	0.08 ± 0.10
Total	41	0.38	110	1.04	39	0.39	152	1.40

***P*<0.01 vs. respective control group; †*P*<0.05 vs. respective control group; ††*P*<0.01 vs. respective control group. ^aSingle base pair deletion mutation; ^bDeletion mutation of more than two base pairs.

in KBrO₃-treated mice, specific MFs of deletion mutations were increased (Table 7 and 8), consistent with the spectrum analysis of *gpt* mutants. In both genotypes and at both time points, NFT treatment did not change Spi⁻ MFs (Table 6).

Discussion

It is well known that transcriptional upregulation of various antioxidant enzymes, including NQO1 and HO1, is regulated by NRF2, which protect cells from oxidative

stress^{25, 26}. In several studies, *Nrf2*^{-/-} mice showed higher sensitivity to various toxicants that induced oxidative stress²⁷⁻³¹. In fact, the mRNA expression level of *Nqo1* in the kidneys of vehicle-treated *Nrf2*^{-/-} mice was significantly lower than that of vehicle-treated *Nrf2*^{+/+} mice, and there was no elevation of the level in KBrO₃- or NFT-treated *Nrf2*^{-/-} mice despite the elevation in *Nrf2*^{+/+} mice. Thus, in the present study, *Nrf2*^{-/-} mice were confirmed to be susceptible to oxidative stress. As previously reported, using this highly oxidative stress-sensitive animal gives us important knowledge about the involvement of oxidative stress in chemical-induced genotoxicity and carcinogenesis²⁷⁻³¹.

Four or thirteen weeks of administration of 1,500 ppm KBrO₃ in drinking water significantly increased the level of 8-OHdG in the kidneys of both genotypes. At both time points, the degree of 8-OHdG increase was higher in *Nrf2*^{-/-} mice than in *Nrf2*^{+/+} mice. Meanwhile, increases in *gpt* and Spi⁻ MFs were detected, and the tendencies of the degrees of increase in *gpt* and Spi⁻ MFs at 13 weeks of exposure were the same as those of 8-OHdG. In the spectrum analysis of *gpt* and Spi⁻ mutants in KBrO₃-treated *Nrf2*^{-/-} mice, specific MFs of deletion mutations were increased, consistent with a previous study of rats²⁴, and they were accompanied by an increase in the frequencies of deletion mutations of more than two base pairs. An *in vitro* report demonstrated that error in the repair process of 8-OHdG induced by KBrO₃ treatment caused double-strand breaks (DSBs) in human cells and that DSBs resulted in a large deletion³⁸. Considering these mechanisms, the increase in size of deletion mutations might reflect the accumulation of high amounts

Table 6. Spi⁻ MFs in the Kidneys of *Nrf2*^{+/+} or *Nrf2*^{-/-} *gpt* Delta Mice Treated with KBrO₃ or NFT for 4 or 13 Weeks

Treatment period	Genotype	Treatment	No. of animals	MF#
4 weeks	<i>Nrf2</i> ^{+/+}	Control	4	0.24 ± 0.13
		1,500 ppm KBrO ₃	5	0.43 ± 0.16
		2,500 ppm NFT	5	0.30 ± 0.13
	<i>Nrf2</i> ^{-/-}	Control	4	0.18 ± 0.05
		1,500 ppm KBrO ₃	4	0.36 ± 0.10
		2,500 ppm NFT	5	0.26 ± 0.07
13 weeks	<i>Nrf2</i> ^{+/+}	Control	8	0.31 ± 0.06
		1,500 ppm KBrO ₃	8	0.85 ± 0.16**
		2,500 ppm NFT	7	0.33 ± 0.07
	<i>Nrf2</i> ^{-/-}	Control	5	0.28 ± 0.06
		1,500 ppm KBrO ₃	8	0.92 ± 0.28††
		2,500 ppm NFT	8	0.36 ± 0.14

**P*<0.05 vs. respective control group; ** *P*<0.01 vs. respective control group. ††*P*<0.01 vs. respective control group; MF, Mutant frequency; #Means ± SD. Spi⁻ assays were performed in two divided groups: the 4-week treatment group and 13-week treatment group.

Table 7. Mutation Spectra of Spi⁻ Plaques in the Kidneys of *Nrf2*^{+/+} or *Nrf2*^{-/-} *gpt* Delta Mice Treated with KBrO₃ or NFT for 4 Weeks

		Control		1,500 ppm KBrO ₃		2,500 ppm NFT	
		Number (%)	Mutation frequencies (10 ⁻⁵)	Number (%)	Mutation frequencies (10 ⁻⁵)	Number (%)	Mutation frequencies (10 ⁻⁵)
<i>Nrf2</i> ^{+/+}	Single bp deletion						
	Simple						
	G or C	6 (25.0)	0.06 ± 0.04	6 (9.2)	0.04 ± 0.05	6 (12.0)	0.03 ± 0.03
	A or T	0	0	5 (7.7)	0.03 ± 0.04	1 (2.0)	0.01 ± 0.01
	In run						
	G or C	4 (16.7)	0.04 ± 0.03	17 (26.2)	0.12 ± 0.08	15 (30.0)	0.09 ± 0.09
	A or T	5 (20.8)	0.05 ± 0.03	18 (27.7)	0.11 ± 0.09	13 (26.0)	0.08 ± 0.04
	2 to 1 kb deletion ^a	0	0	5 (7.7)	0.03 ± 0.04	0	0
	Over 1 kb deletion ^b	8 (33.3)	0.08 ± 0.10	12 (18.5)	0.08 ± 0.11	12 (24.0)	0.07 ± 0.07
	Complex	1 (4.2)	0.01 ± 0.02	2 (3.1)	0.01 ± 0.03	1 (2.0)	0.01 ± 0.01
	Insertion	0	0	0	0	1 (2.0)	0.01 ± 0.02
	Base substitution	0	0	0	0	1 (2.0)	0.00 ± 0.01
	Total	24	0.24	65	0.43	50	0.30
<i>Nrf2</i> ^{-/-}	Single bp deletion						
	Simple						
	G or C	0	0	7 (20.6)	0.08 ± 0.05	3 (7.9)	0.02 ± 0.02
	A or T	2 (8.0)	0.01 ± 0.02	2 (5.9)	0.02 ± 0.02	0	0
	In run						
	G or C	7 (28.0)	0.04 ± 0.03	9 (26.5)	0.10 ± 0.09	12 (31.6)	0.08 ± 0.05
	A or T	8 (32.0)	0.06 ± 0.08	8 (23.5)	0.09 ± 0.06	11 (28.9)	0.08 ± 0.05
	2 to 1 kb deletion ^a	0	0	3 (8.8)	0.03 ± 0.04	0	0
	Over 1 kb deletion ^b	8 (32.0)	0.07 ± 0.06	4 (11.8)	0.04 ± 0.04	12 (31.6)	0.08 ± 0.05
	Complex	0	0	1 (2.9)	0.01 ± 0.01	0	0
	Insertion	0	0	0	0	0	0
	Base substitution	0	0	0	0	0	0
	Total	25	0.18	34	0.36	38	0.26

^aDeletion mutation of two or more but less than one thousand base pairs. ^bDeletion mutation of more than one thousand base pairs.

of 8-OHdG in the nuclei due to KBrO₃. These results suggested that the formation of 8-OHdG induced by oxidative stress was directly involved in the increase of deletion mutations in KBrO₃-treated animals. It was suspected that the formation of high amounts of 8-OHdG owing to the strong potential of KBrO₃ as an oxidizing agent might exceed the repairing capacity of base excision repair enzymes.

Four or thirteen weeks of administration of 2,500 ppm NFT in diet did not increase the level of 8-OHdG in the kidneys of either genotype. In our previous study, the level of 8-OHdG was increased in the kidneys of *Nrf2*^{-/-} mice by oral administration of NFT at 70 mg/kg³⁹. The lower exposure levels of NFT in the present study compared with those in our previous study might be a cause of the static level of 8-OHdG. On the other hand, 13 weeks administration of 2,500 ppm NFT in diet significantly increased *gpt* MFs with guanine base substitution mutations in the kidneys of both genotypes. The degree of increase in *gpt* MFs was higher in *Nrf2*^{-/-} mice than in *Nrf2*^{+/+} mice. These results implied that the vulnerability to oxidative stress caused by the deficiency of *Nrf2* leads to more mutations in NFT-treated mice. Thus, in the genotoxic mechanism of NFT, the formation of 8-OHdG induced by oxidative stress might not be involved in the increase of guanine base substitution mutations. Considering our previous studies, which suggested the involvement of oxidative stress in the chemical structure-related genotoxic mechanism of NFT in rodents^{24, 38}, factors other than 8-OHdG might be crucial to the genotoxicity of NFT,

though the present study did not identify them.

In recent years, the level of 8-OHdG has been frequently used as a marker of oxidative stress in human diseases^{40, 41}. In addition, some reports demonstrated the involvement of oxidative stress in chemical-induced genotoxicity and carcinogenesis using the increase in 8-OHdG level as a parameter of oxidative stress in experimental animals²⁷⁻³¹. However, the relationship between the formation of 8-OHdG and subsequent mutations, including deletion mutations and G:C to T:A transversions, had not been clarified. The revelation of the relationship between 8-OHdG and several types of mutations induced by KBrO₃ or NFT provides new insight into oxidative stress-related *in vivo* mutagenicity.

The present study demonstrated that the formation of 8-OHdG, which resulted from the oxidizing potential of KBrO₃, was directly involved in the increase of deletion mutations; however, oxidative stress-related factors other than 8-OHdG might play a critical role in NFT-induced guanine base substitution mutations. This was the first study to investigate the relationship between 8-OHdG and several types of mutations caused by oxidative stress-inducing chemicals. Accumulation of detailed examinations like this, such as further research on 8-OHdG with respect to individual chemical substances, will lead to accurate risk assessment of oxidative stress in carcinogenicity.

Disclosure of Potential Conflicts of Interest: The authors declare that they have no competing interests.

Table 8. Mutation Spectra of Spi- Plaques in the Kidneys of *Nrf2*^{+/+} or *Nrf2*^{-/-} *gpt* Delta Mice Treated with KBrO₃ or NFT for 13 Weeks

		Control		1,500 ppm KBrO ₃		2,500 ppm NFT	
		Number (%)	Mutation frequencies (10 ⁻⁵)	Number (%)	Mutation frequencies (10 ⁻⁵)	Number (%)	Mutation frequencies (10 ⁻⁵)
<i>Nrf2</i> ^{+/+}	Single bp deletion						
	Simple G or C	10 (13.7)	0.04 ± 0.03	24 (12.8)	0.11 ± 0.07*	6 (12.8)	0.05 ± 0.05
	A or T	2 (2.7)	0.01 ± 0.02	13 (7.0)	0.05 ± 0.04*	2 (4.3)	0.01 ± 0.02
	In run G or C	20 (27.4)	0.09 ± 0.05	60 (32.1)	0.27 ± 0.09**	22 (46.8)	0.16 ± 0.10
	A or T	28 (38.4)	0.12 ± 0.06	63 (33.7)	0.29 ± 0.10**	10 (21.3)	0.06 ± 0.06
	2 to 1 kb deletion ^a	1 (1.4)	0.00 ± 0.01	12 (6.4)	0.05 ± 0.05*	0	0
	Over 1 kb deletion ^b	12 (16.4)	0.05 ± 0.03	15 (8.0)	0.08 ± 0.06	4 (8.5)	0.02 ± 0.03
	Complex	0	0	0	0	1 (2.1)	0.00 ± 0.01
	Insertion	0	0	0	0	0	0
	Base substitution	0	0	0	0	2 (4.3)	0.01 ± 0.03
Total		73	0.31	187	0.85	47	0.33
<i>Nrf2</i> ^{-/-}	Single bp deletion						
	Simple G or C	13 (28.3)	0.09 ± 0.07	17 (10.8)	0.10 ± 0.09	5 (7.0)	0.03 ± 0.05
	A or T	1 (2.2)	0.00 ± 0.01	15 (9.6)	0.10 ± 0.11†	3 (4.2)	0.02 ± 0.02
	In run G or C	6 (13.0)	0.04 ± 0.03	44 (28.0)	0.23 ± 0.09††	24 (33.8)	0.12 ± 0.07†
	A or T	22 (47.8)	0.13 ± 0.07	50 (31.8)	0.31 ± 0.13†	20 (28.2)	0.10 ± 0.06
	2 to 1 kb deletion ^a	0	0	19 (12.1)	0.13 ± 0.09††	3 (4.2)	0.02 ± 0.03
	Over 1 kb deletion ^b	4 (8.7)	0.02 ± 0.04	11 (7.0)	0.05 ± 0.07	14 (19.7)	0.08 ± 0.07
	Complex	0	0	0	0	0	0
	Insertion	0	0	0	0	1 (1.4)	0.01 ± 0.02
	Base substitution	0	0	1 (0.6)	0.00 ± 0.01	1 (1.4)	0.00 ± 0.01
Total		46	0.28	157	0.92	71	0.36

P* < 0.05 vs. respective control group; *P* < 0.01 vs. respective control group. †*P* < 0.05 vs. respective control group; ††*P* < 0.01 vs. respective control group. ^aDeletion mutation of two or more but less than one thousand base pairs. ^bDeletion mutation of more than one thousand base pairs.

References

- Murata M, Midorikawa K, and Kawanishi S. Oxidative DNA damage and mammary cell proliferation by alcohol-derived salsolinol. *Chem Res Toxicol*. **26**: 1455–1463. 2013. [[Medline](#)] [[CrossRef](#)]
- Rundhaug JE, and Fischer SM. Molecular mechanisms of mouse skin tumor promotion. *Cancers (Basel)*. **2**: 436–482. 2010. [[Medline](#)] [[CrossRef](#)]
- Klaunig JE, Xu Y, Isenberg JS, Bachowski S, Kolaja KL, Jiang J, Stevenson DE, and Walborg EF Jr. The role of oxidative stress in chemical carcinogenesis. *Environ Health Perspect*. **106**(Suppl 1): 289–295. 1998. [[Medline](#)] [[CrossRef](#)]
- Saha SK, Lee SB, Won J, Choi HY, Kim K, Yang GM, Dayem AA, and Cho SG. Correlation between oxidative stress, nutrition, and cancer initiation. *Int J Mol Sci*. **18**: 1544. 2017. [[Medline](#)] [[CrossRef](#)]
- Okazaki K, Ishii Y, Kitamura Y, Maruyama S, Umemura T, Miyauchi M, Yamagishi M, Imazawa T, Nishikawa A, Yoshimura Y, Nakazawa H, and Hirose M. Dose-dependent promotion of rat forestomach carcinogenesis by combined treatment with sodium nitrite and ascorbic acid after initiation with N-methyl-N'-nitro-N-nitrosoguanidine: possible contribution of nitric oxide-associated oxidative DNA damage. *Cancer Sci*. **97**: 175–182. 2006. [[Medline](#)] [[CrossRef](#)]
- Umemura T, Kodama Y, Kurokawa Y, and Williams GM. Lack of oxidative DNA damage or initiation of carcinogenesis in the kidneys of male F344 rats given subchronic exposure to p-dichlorobenzene (pDCB) at a carcinogenic dose. *Arch Toxicol*. **74**: 54–59. 2000. [[Medline](#)] [[CrossRef](#)]
- Kasai H, and Nishimura S. Formation of 8-hydroxydeoxyguanosine in DNA by oxygen radicals and its biological significance. In: *Oxidative Stress: Oxidants and Antioxidants*. H Sies. Academic Press, London. 99–116. 1991.
- Michaels ML, Pham L, Cruz C, and Miller JH. MutM, a protein that prevents G.C→T.A transversions, is formamidopyrimidine-DNA glycosylase. *Nucleic Acids Res*. **19**: 3629–3632. 1991. [[Medline](#)] [[CrossRef](#)]
- Nakabeppu Y. Cellular levels of 8-oxoguanine in either DNA or the nucleotide pool play pivotal roles in carcinogenesis and survival of cancer cells. *Int J Mol Sci*. **15**: 12543–12557. 2014. [[Medline](#)] [[CrossRef](#)]
- Nohmi T, Kim SR, and Yamada M. Modulation of oxidative mutagenesis and carcinogenesis by polymorphic forms of human DNA repair enzymes. *Mutat Res*. **591**: 60–73. 2005. [[Medline](#)] [[CrossRef](#)]
- Ishidate M Jr, Sofuni T, Yoshikawa K, Hayashi M, Nohmi T, Sawada M, and Matsuoka A. Primary mutagenicity screening of food additives currently used in Japan. *Food Chem Toxicol*. **22**: 623–636. 1984. [[Medline](#)] [[CrossRef](#)]
- Ishidate M Jr, and Yoshikawa K. Chromosome aberration tests with Chinese hamster cells in vitro with and without metabolic activation—a comparative study on mutagens and carcinogens. *Arch Toxicol Suppl*. **4**: 41–44. 1980. [[Medline](#)] [[CrossRef](#)]
- Hayashi M, Kishi M, Sofuni T, and Ishidate M Jr. Micro-nucleus tests in mice on 39 food additives and eight miscellaneous chemicals. *Food Chem Toxicol*. **26**: 487–500. 1988. [[Medline](#)] [[CrossRef](#)]
- Umemura T, Kitamura Y, Kanki K, Maruyama S, Okazaki K, Imazawa T, Nishimura T, Hasegawa R, Nishikawa A, and Hirose M. Dose-related changes of oxidative stress and cell proliferation in kidneys of male and female F344 rats exposed to potassium bromate. *Cancer Sci*. **95**: 393–398. 2004. [[Medline](#)] [[CrossRef](#)]
- Ballmaier D, and Epe B. Oxidative DNA damage induced by potassium bromate under cell-free conditions and in mammalian cells. *Carcinogenesis*. **16**: 335–342. 1995. [[Medline](#)] [[CrossRef](#)]
- Umemura T, Sai K, Takagi A, Hasegawa R, and Kurokawa Y. A possible role for cell proliferation in potassium bromate (KBrO₃) carcinogenesis. *J Cancer Res Clin Oncol*. **119**: 463–469. 1993. [[Medline](#)] [[CrossRef](#)]
- Kasai H, Nishimura S, Kurokawa Y, and Hayashi Y. Oral administration of the renal carcinogen, potassium bromate, specifically produces 8-hydroxydeoxyguanosine in rat target organ DNA. *Carcinogenesis*. **8**: 1959–1961. 1987. [[Medline](#)] [[CrossRef](#)]
- Murata M, Bansho Y, Inoue S, Ito K, Ohnishi S, Midorikawa K, and Kawanishi S. Requirement of glutathione and cysteine in guanine-specific oxidation of DNA by carcinogenic potassium bromate. *Chem Res Toxicol*. **14**: 678–685. 2001. [[Medline](#)] [[CrossRef](#)]
- Umemura T, Kanki K, Kuroiwa Y, Ishii Y, Okano K, Nohmi T, Nishikawa A, and Hirose M. *In vivo* mutagenicity and initiation following oxidative DNA lesion in the kidneys of rats given potassium bromate. *Cancer Sci*. **97**: 829–835. 2006. [[Medline](#)] [[CrossRef](#)]
- IARC Working Group on the Evaluation of the Carcinogenic Risk to Humans Nitrofurantoin. IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans, Vol. 50. Lyon. 211–231. 1990.
- Chung MC, Bosquesi PL, and dos Santos JL. A prodrug approach to improve the physico-chemical properties and decrease the genotoxicity of nitro compounds. *Curr Pharm Des*. **17**: 3515–3526. 2011. [[Medline](#)] [[CrossRef](#)]
- Boelsterli UA, Ho HK, Zhou S, and Leow KY. Bioactivation and hepatotoxicity of nitroaromatic drugs. *Curr Drug Metab*. **7**: 715–727. 2006. [[Medline](#)] [[CrossRef](#)]
- Bartel LC, Montalto de Mecca M, and Castro JA. Nitro-reductive metabolic activation of some carcinogenic nitro heterocyclic food contaminants in rat mammary tissue cellular fractions. *Food Chem Toxicol*. **47**: 140–144. 2009. [[Medline](#)] [[CrossRef](#)]
- Kijima A, Ishii Y, Takasu S, Matsushita K, Kuroda K, Hibi D, Suzuki Y, Nohmi T, and Umemura T. Chemical structure-related mechanisms underlying *in vivo* genotoxicity induced by nitrofurantoin and its constituent moieties in *gpt* delta rats. *Toxicology*. **331**: 125–135. 2015. [[Medline](#)] [[CrossRef](#)]
- Lee JS, and Surh YJ. Nrf2 as a novel molecular target for chemoprevention. *Cancer Lett*. **224**: 171–184. 2005. [[Medline](#)] [[CrossRef](#)]
- Jaiswal AK. Regulation of genes encoding NAD(P)H:quinone oxidoreductases. *Free Radic Biol Med*. **29**: 254–262. 2000. [[Medline](#)] [[CrossRef](#)]
- Yokoo Y, Kijima A, Ishii Y, Takasu S, Tsuchiya T, and Umemura T. Effects of *Nrf2* silencing on oxidative stress-associated intestinal carcinogenesis in mice. *Cancer Med*. **5**: 1228–1238. 2016. [[Medline](#)] [[CrossRef](#)]
- Umemura T, Kuroiwa Y, Kitamura Y, Ishii Y, Kanki K, Kodama Y, Itoh K, Yamamoto M, Nishikawa A, and Hirose M. A crucial role of Nrf2 in *in vivo* defense against oxidative damage by an environmental pollutant, pentachlorophenol.

- Toxicol Sci. **90**: 111–119. 2006. [[Medline](#)] [[CrossRef](#)]
29. Tasaki M, Kuroiwa Y, Inoue T, Hibi D, Matsushita K, Kijima A, Maruyama S, Nishikawa A, and Umemura T. Lack of *nrf2* results in progression of proliferative lesions to neoplasms induced by long-term exposure to non-genotoxic hepatocarcinogens involving oxidative stress. *Exp Toxicol Pathol*. **66**: 19–26. 2014. [[Medline](#)] [[CrossRef](#)]
30. Kitamura Y, Umemura T, Kanki K, Kodama Y, Kitamoto S, Saito K, Itoh K, Yamamoto M, Masegi T, Nishikawa A, and Hirose M. Increased susceptibility to hepatocarcinogenicity of Nrf2-deficient mice exposed to 2-amino-3-methylimidazo[4,5-*f*]quinoline. *Cancer Sci*. **98**: 19–24. 2007. [[Medline](#)] [[CrossRef](#)]
31. Kanki K, Umemura T, Kitamura Y, Ishii Y, Kuroiwa Y, Kodama Y, Itoh K, Yamamoto M, Nishikawa A, and Hirose M. A possible role of *nrf2* in prevention of renal oxidative damage by ferric nitrilotriacetate. *Toxicol Pathol*. **36**: 353–361. 2008. [[Medline](#)] [[CrossRef](#)]
32. Nohmi T, Suzuki T, and Masumura K. Recent advances in the protocols of transgenic mouse mutation assays. *Mutat Res*. **455**: 191–215. 2000. [[Medline](#)] [[CrossRef](#)]
33. Matsushita K, Ishii Y, Takasu S, Kuroda K, Kijima A, Tsuchiya T, Kawaguchi H, Miyoshi N, Nohmi T, Ogawa K, Nishikawa A, and Umemura T. A medium-term *gpt* delta rat model as an *in vivo* system for analysis of renal carcinogenesis and the underlying mode of action. *Exp Toxicol Pathol*. **67**: 31–39. 2015. [[Medline](#)] [[CrossRef](#)]
34. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, and Nabeshima Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. *Biochem Biophys Res Commun*. **236**: 313–322. 1997. [[Medline](#)] [[CrossRef](#)]
35. Kurokawa Y, Maekawa A, Takahashi M, and Hayashi Y. Toxicity and carcinogenicity of potassium bromate—a new renal carcinogen. *Environ Health Perspect*. **87**: 309–335. 1990. [[Medline](#)]
36. French JE. Toxicology and carcinogenesis studies of nitrofurantoin (CAS NO. 67–20–9) in F344/N rats and B6C3F₁ mice (feed studies). 1989, from National Toxicology Program website: https://ntp.niehs.nih.gov/ntp/htdocs/lt_rpts/tr341.pdf.
37. Umemura T, Kai S, Hasegawa R, Kanki K, Kitamura Y, Nishikawa A, and Hirose M. Prevention of dual promoting effects of pentachlorophenol, an environmental pollutant, on diethylnitrosamine-induced hepato- and cholangiocarcinogenesis in mice by green tea infusion. *Carcinogenesis*. **24**: 1105–1109. 2003. [[Medline](#)] [[CrossRef](#)]
38. Luan Y, Suzuki T, Palanisamy R, Takashima Y, Sakamoto H, Sakuraba M, Koizumi T, Saito M, Matsufuji H, Yamagata K, Yamaguchi T, Hayashi M, and Honma M. Potassium bromate treatment predominantly causes large deletions, but not GC>TA transversion in human cells. *Mutat Res*. **619**: 113–123. 2007. [[Medline](#)] [[CrossRef](#)]
39. Tsuchiya T, Kijima A, Ishii Y, Takasu S, Yokoo Y, Nishikawa A, Yanai T, and Umemura T. Role of oxidative stress in the chemical structure-related genotoxicity of nitrofurantoin in *Nrf2*-deficient *gpt* delta mice. *J Toxicol Pathol*. **31**: 169–178. 2018.
40. Il'yasova D, Scarbrough P, and Spasojevic I. Urinary biomarkers of oxidative status. *Clin Chim Acta*. **413**: 1446–1453. 2012. [[Medline](#)] [[CrossRef](#)]
41. Di Minno A, Turnu L, Porro B, Squellerio I, Cavalca V, Tremoli E, and Di Minno MND. 8-hydroxy-2-deoxyguanosine levels and cardiovascular disease: a systematic review and meta-analysis of the literature. *Antioxid Redox Signal*. **24**: 548–555. 2016. [[Medline](#)] [[CrossRef](#)]